NOV 14, 2019 10:30 AM PST

Identifying the PIK3CA mutations that make a difference in breast cancer with the QIAGEN therascreen® PIK3CA RGQ PCR Kit

Sponsored by: QIAGEN
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Global Product Manager, Oncology & Precision Diagnostics, QIAGEN
    Biography
      Ben is a member of the Oncology Diagnostics Global Product Management team at QIAGEN, with responsibility for commercialisation of innovative new Companion Diagnostic tests around the world, including the therascreen FGFR RGQ RT-PCR Kit recently approved by the FDA in the USA.

      A molecular biologist and immunologist by qualification, he has over a decade of experience in the IVD industry covering a range of roles including assay development, manufacturing and product management.

      He is based in Manchester, UK, the QIAGEN global centre of excellence for companion diagnostic development, where the FGFR RGQ RT-PCR Kit was originally developed.

    Abstract

    Breast cancer is the most frequently occurring form of cancer in women.  Whilst 5-year survival rates for localized disease approach 99%, cases of advanced breast cancer have a much poorer prognosis, with 5-year survival of around 27%.  Therefore, new treatment modalities for this indication are clearly welcome.  The Novartis drug PIQRAYTM (alpelisib) is the first -selective PI3Kinase inhibitor to be approved by the FDA for treatment of cases of advanced Hormone Receptor +ve / HER2 -ve breast cancer that also harbour activating mutations in the PIK3CA gene.  There are present in about 40% of cases, and therefore, it is necessary to use a companion diagnostic (CDx) test to identify patients eligible for treatment.  The therascreen PIK3CA RGQ PCR Kit is a rapid and reliable test, able to detect the presence of any of the 11 clinically actionable PIK3CA mutations in DNA from both FFPE tumor tissue and plasma specimens.  Clinically validated during the SOLAR-1 clinical trial, this test is currently the only FDA-approved CDx for this indication.  Available in the USA since May 2019, the Kit supports the delivery of precision medicine to patients for whom few other treatment options may remain.


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    APR 21, 2021 10:00 AM PDT
    C.E. CREDITS
    APR 21, 2021 10:00 AM PDT
    Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
    APR 20, 2021 11:00 AM PDT
    C.E. CREDITS
    APR 20, 2021 11:00 AM PDT
    Date: April 20, 2021 Time: 11:00am (PST), 2:00pm (EST) Identification and confirmation of microbial isolates is crucial in the analysis workflow, providing decision-makers the information...
    NOV 14, 2019 10:30 AM PST

    Identifying the PIK3CA mutations that make a difference in breast cancer with the QIAGEN therascreen® PIK3CA RGQ PCR Kit

    Sponsored by: QIAGEN
    C.E. Credits: P.A.C.E. CE Florida CE

    Specialty

    Molecular Biology

    Cell Biology

    Immunology

    Pcr/rt-Pcr/real-Time Pcr

    Laboratory Testing

    Gene Expression

    Biotechnology

    Antibodies

    Molecular Diagnostics

    Biomarkers

    Clinical Research

    Microbiology

    Gene Sequencing

    Biochemistry

    Dna Sequencing

    Geography

    Asia57%

    North America43%

    Registration Source

    Website Visitors57%

    Email Promotions14%

    Trending Newsletter Promotion14%

    Other14%

    Job Title

    Student25%

    Educator/Faculty25%

    Medical Laboratory Technician25%

    Veterinarian25%

    Organization

    Academic Institution43%

    Veterinary School14%

    Medical School14%

    Consultant14%

    Research Institute14%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more